Tag: Cardiovascular Data

Cost-related medication nonadherence associated with increased ED utilization

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

byDeepti Shroff

July 15, 2026

1. The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist cleared ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

Chemotherapy exposure is independently associated with reduced pain severity in advanced pancreatic cancer
Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment
Spinal instability may be the primary cause of pain in sacral metastases as opposed to neurologic compromise

No Result

View All Result